Not waving but drowning: Takeda's blood cancer drug flunks phase 3, dealing further blow to hopes of approval flurry

Takeda’s Wave 1 pipeline is threatening to peter out into a ripple. The latest setback comes from a phase 3 blood cancer clinical trial, which found adding pevonedistat to chemotherapy did nothing to improve event-free survival.